Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

ClinicalTrials.gov ID: NCT00038506

Public ClinicalTrials.gov record NCT00038506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 11:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)

Study identification

NCT ID
NCT00038506
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
ViiV Healthcare
Industry
Enrollment
100 participants

Conditions and interventions

Conditions

Interventions

  • abacavir/lamivudine/zidovudine Drug
  • tenofovir Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2002
Primary completion
Jul 31, 2004
Completion
Jul 31, 2004
Last update posted
Apr 7, 2015

2002 – 2004

United States locations

U.S. sites
27
U.S. states
11
U.S. cities
25
Facility City State ZIP Site status
GSK Investigational Site Los Angeles California 90027
GSK Investigational Site San Rafael California 94903
GSK Investigational Site Fort Lauderdale Florida 33145
GSK Investigational Site Jacksonville Florida 32206
GSK Investigational Site Lake Worth Florida 33463
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Miami Beach Florida 33139
GSK Investigational Site North Miami Florida 33161
GSK Investigational Site Orlando Florida 32804
GSK Investigational Site Tallahassee Florida 32303
GSK Investigational Site Atlanta Georgia 30309
GSK Investigational Site Decatur Georgia 30033
GSK Investigational Site Chicago Illinois 60657
GSK Investigational Site Maywood Illinois 60153
GSK Investigational Site Lafayette Indiana 47904
GSK Investigational Site Berkeley Michigan 48072
GSK Investigational Site New York New York 10014
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Valhalla New York 10595
GSK Investigational Site Tulsa Oklahoma 74114
GSK Investigational Site Arlington Texas 76015
GSK Investigational Site Dallas Texas 75208
GSK Investigational Site Dallas Texas 75216
GSK Investigational Site Dallas Texas 75246
GSK Investigational Site Houston Texas 77004
GSK Investigational Site Seattle Washington 98104
GSK Investigational Site Green Bay Wisconsin 54301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00038506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2015 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00038506 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →